Navigation Links
Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
Date:7/2/2010

competing products has been demonstrated in five clinical trials.  The product is also available under the trade name PROCHIEVE® and available in both a 4% and 8% concentrations. PROCHIEVE® 4% is indicated for the treatment of secondary amenorrhea.

A Phase 3 clinical program called the PREGNANT (PROCHIEVE® Extending GestatioN A New Therapy) Study is currently underway to evaluate the safety and efficacy of PROCHIEVE® 8% (progesterone gel) to reduce the risk of pre-term birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy. The primary endpoint of this study is a reduction in the incidence of pre-term birth at less than or equal to 32 weeks gestation vs. placebo. With enrollment in the program complete, preliminary top-line study results are expected at the end of 2010. If the data is positive, a NDA filing will follow in 2011. Pre-term birth occurs in one of every eight live born infants, and short cervix is the single most important predictor of pre-term birth.  There are currently no products approved for the prevention of pre-term birth.

Important Safety Information

The most common side effects of CRINONE® include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain.  CRINONE® is contraindicated in patients with an active thrombophlebitis or thromboembolic disorders, or a history of thrombophlebitis or thromboembolic disorders, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  Watson is engaged in the development and distribution of
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( ... announced today that the United States Food and Drug ... application(IND) for ORMD-0801, its oral insulin capsule. ... to proceed," stated Nadav Kidron , ... milestone for Oramed and we look forward to continuing ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Research (A*STAR) and Switzerland,s Cytos Biotechnology ... dosed in a Phase 1 clinical trial with their H1N1 ... particle (VLP) technology. In this first Phase 1 clinical trial, ... its potential to protect against H1N1 influenza infection will be ...
(Date:5/16/2013)... May 16, 2013  Nektar Therapeutics, (Nasdaq: NKTR ... Robin , is scheduled to present at the upcoming ... at the Sheraton New York Hotel on Tuesday, ... The presentation will be accessible via a Webcast through a ... the Nektar website: http://www.nektar.com . This Webcast will be ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... NVAX ) today announced financial results for the third quarter ... of $10.4 million, or $0.10 per share, for the third quarter ... $0.08 per share, for the third quarter of 2009.  For the ... million, or $0.30 per share, compared to a net loss of ...
... PITTSBURGH, Nov. 4, 2010 Carnegie Mellon University,s ... soldiers who have lost limbs in combat. ... CMU,s Jeffrey O. Hollinger, director of the ... three-year, $2.9 million U.S. Department of Defense research ...
Cached Medicine Technology:NOVAVAX Reports Third Quarter 2010 Financial Results 2NOVAVAX Reports Third Quarter 2010 Financial Results 3NOVAVAX Reports Third Quarter 2010 Financial Results 4NOVAVAX Reports Third Quarter 2010 Financial Results 5NOVAVAX Reports Third Quarter 2010 Financial Results 6CMU's Bone Tissue Engineering Center Receives Defense Department Research Grant to Help Injured Soldiers 2
(Date:5/18/2013)... 2013 Dr. Robert Tracey, an area leader ... employs his knowledge of the root causes of sleep apnea ... May being Better Sleep Month, Dr. Tracey points out estimates ... sleep disorder, and sleep apnea is one of the most ... will essentially stop breathing at different times while sleeping. When ...
(Date:5/18/2013)... Wisconsin (PRWEB) May 18, 2013 Scott Tischler ... in 90 days. These five keys to losing weight played ... help and support of Scott Tischler, Troy was able to ... that any weight loss program should be approached with caution ... pain. These are the five keys to weight loss that ...
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 John Ravera, ... announced the addition of a new member to his dental ... has worked in the field for over 10 years. She ... with honors, and was elected a member of Sigma Pi ... hygiene profession. Marino enjoys working with patients of all ages, ...
(Date:5/18/2013)... 2013 Kimono condoms assorted sampler ... condom store recently announced. Condomania recently added new ... selection of condoms from all over the world. ... to try different condom styles from one of the ... classic comfortable shape and secure, the new packs contain ...
(Date:5/18/2013)... May 18, 2013 According to the the ... as Toxic Epidermal Necrolysis, is a severe allergic reaction usually ... flu-like symptoms but it can quickly advance causing blistering and ... even cause death. SJS can develop at any time ... the former NBA player, Manute Bol, passed away after he ...
Breaking Medicine News(10 mins):Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:Kimono Condoms Assorted Sampler Packs Now Available at Condomania 2Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2
... a state of serious impairments in both learning ability ... one of the most prevalent conditions in child psychiatry, ... adulthood. ADHD is conservatively estimated to occur in 3,07,5% ... permissive criteria yield estimates of up to 17% (Barbaresi ...
... Just one week after,Cover All Pennsylvanians, the ... the General Assembly, Governor Edward G.,Rendell today visited ... "Tour to,Insure." The five-day, nine-stop tour has highlighted ... coverage. The Lehigh Valley has nearly 37,000,uninsured adults., ...
... no difference in motorists, reaction times , , SATURDAY, Oct. ... pain medications such as morphine does not impair a ... at Rush University Medical Center in Chicago compared two ... morphine and 49 who weren,t taking any pain medication. ...
... Holdings, Inc. (Nasdaq: NHWK ), a leading provider ... today announced that,it will host a conference call on ... to review the company,s third quarter results. Conference ... call will be held on Wednesday, October,31, 2007 at ...
... Medical Injustice, Will Challenge,Corporate-Backed Proponents of "Health Courts", ... Dale Nance, co-author of the groundbreaking new report ... the featured speakers at a,patient safety forum in ... debate the merits and weaknesses of the health ...
... SAN DIEGO, Oct. 12 MediKeeper,( http://www.medikeeper.com ), ... and wellness industry, has closed its Series A ... MediKeeper was started in 2003 by a ... of making medical records secure, mobile,and accessible online. ...
Cached Medicine News:Health News:Computerized training of working memory is a promising therapeutic strategy in ADHD 2Health News:Computerized training of working memory is a promising therapeutic strategy in ADHD 3Health News:Governor Rendell's 'Tour to Insure' Urges Passage of Plan to Give Access to Affordable Health Insurance 2Health News:Governor Rendell's 'Tour to Insure' Urges Passage of Plan to Give Access to Affordable Health Insurance 3Health News:Morphine Painkillers Won't Impair Driving 2Health News:NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call 2Health News:'Health Courts' Critic to be Featured Speaker at Wyoming Patient Safety Panel 2Health News:MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: